Targovax ASA ( (GB:0RIS) ) has provided an update.
Circio Holding ASA’s subsidiary, Circio AB, has entered a research evaluation agreement with Lonza to test its circVec circular mRNA expression technology in Lonza’s protein production system. This collaboration could enhance Circio’s industry positioning by demonstrating the potential of its circVec platform to become a new standard in nucleic acid and viral therapeutics, benefiting stakeholders through improved therapeutic solutions.
More about Targovax ASA
Circio Holding ASA is a biotechnology company focused on developing advanced circular RNA vector expression technology for next-generation nucleic acid medicine. The company has created a unique circRNA vector expression platform for DNA, RNA, and viral therapeutics, which offers enhanced and durable protein expression compared to traditional mRNA systems. This technology is applicable in various therapeutic settings, including genetic medicine, cell therapy, and chronic disease.
YTD Price Performance: -93.95%
Average Trading Volume: 23,211
Technical Sentiment Signal: Strong Buy
Current Market Cap: NOK49.56M
For detailed information about 0RIS stock, go to TipRanks’ Stock Analysis page.